Building an international precision medicine platform trial for the acute respiratory distress syndrome (ARDS): an expert consensus project report
Authors:
- Kiran ReddyKRKiran Reddy
- Neil AggarwalNANeil Aggarwal
- Narges Alipanah-LechnerNANarges Alipanah-Lechner
- Djillali AnnaneDADjillali Annane
- David B AntcliffeDADavid B Antcliffe
- Daphne BabalisDBDaphne Babalis
- J Kenneth BaillieJBJ Kenneth Baillie
- Lieuwe Dj BosLBLieuwe Dj Bos
- Aidan BurrellABAidan Burrell
- Carolyn S CalfeeCCCarolyn S Calfee
- Kiki Cano-GamezKCKiki Cano-Gamez
Open Access
- 1 July 2025
- journal article
- Published by National Institute for Health and Care Research in Efficacy and Mechanism Evaluation
- p. 1-43
Abstract
Background: Almost all large-scale trials of disease-modifying therapeutic agents in critical care have failed to show benefit for patients, which may be explained in part by the clinical and biological heterogeneity inherent in virtually all critical illness syndromes. Enrichment strategies have been developed to separate responders from non-responders and better target treatments. In patients with the acute respiratory distress syndrome, a critical illness syndrome involving severe lung inflammation, latent class analysis and other clustering approaches have led to the discovery of subgroups (phenotypes) that appear to respond differently to treatment based on retrospective analyses of published clinical trials and observational cohorts. The next step is to test these phenotypes in a prospective trial. Rapid, point-of-care analytical methods have now made such a trial possible. There is a need to advance treatment for patients with acute respiratory distress syndrome and other critical illness syndromes by incorporating a phenotype-based approach into prospective trial design. The hyperinflammatory and hypoinflammatory phenotypes, that have been identified in acute respiratory distress syndrome, will be the first to be included in such a trial, with scope for further phenotypes to be studied over time. Future work: This Efficacy and Mechanism Evaluation report, through expert consensus, describes a new Phase II, multiarm, adaptive platform randomised controlled trial design that tests multiple pharmacological therapies in a population of patients with acute respiratory distress syndrome stratified by baseline inflammatory phenotype. This report also reviews issues to be considered in developing precision medicine trials in critical care, which are designed with newly developed clinical phenotypes in mind. This work has been used to develop the Precision medicine Adaptive Network platform Trial in Hypoxaemic acutE respiratory failuRe precision medicine trial in acute respiratory distress syndrome, which has been funded and will begin recruitment in June 2025. Limitations: This report is the result of expert consensus review, rather than utilising strict review methodologies (e.g. Delphi consensus process). However, expert consensus has been found to generate similar results to consensus processes when a high degree of agreement is reached and > 70% agreement was reached for all included recommendations. Funding: This article presents independent research funded by the (NIHR) Efficacy and Mechanism Evaluation programme as award number NIHR154493.Keywords
Funding Information
- Efficacy and Mechanism Evaluation Programme (NIHR154493)
This publication has 214 references indexed in Scilit:
- Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19JAMA, 2021
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19JAMA, 2020
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19JAMA, 2020
- Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19JAMA, 2020
- Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin LevelJAMA, 2018
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 CountriesJAMA, 2016
- The Platform TrialJAMA, 2015
- Initial Trophic vs Full Enteral Feeding in Patients With Acute Lung Injury: The EDEN Randomized TrialJAMA, 2012
- Enteral Omega-3 Fatty Acid, γ-Linolenic Acid, and Antioxidant Supplementation in Acute Lung InjuryJAMA, 2011